Improving CAR T cell therapies for more types of cancer
Official title: Expanding CAR T cell applications through high-throughput forward- and reverse immune engineering
Funded at New York University School of Medicine · NIH-10910581 · Data updated 2026-11-12
This study is working on improving CAR T cell therapies to help more cancer patients by creating new types of CAR T cells that can target tougher tumors, giving hope for better treatment options for different kinds of cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $1,525,500 |
| NIH project number | 1DP2CA301080-01 |
| Project ID | NIH-10910581 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with solid tumors that have been resistant to traditional cancer treatments.
✕Less likely to help
Patients with cancers that are already effectively treated by existing therapies may not receive significant benefits from this research.
What this research studies
This research focuses on enhancing CAR T cell therapies, which are designed to harness the body's immune system to fight cancer. The approach involves developing a new class of CAR T cells that can target a wider range of tumors, particularly those that are less mutated and harder to treat. By identifying novel tumor antigens and engineering peptide-centric CAR T cells, the research aims to expand the eligibility for these therapies beyond current limitations. Patients may benefit from more effective treatment options for various types of cancer, including solid tumors.
Why it matters
Potential benefit: If successful, this research could provide patients with access to more effective CAR T cell therapies for a broader range of cancers.
How similar studies have gone: Previous research has shown promise in using CAR T cell therapies for certain cancers, but this approach aims to address a novel and less explored area of solid tumors.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Yarmarkovich, Mark — New York University School of Medicine
- Study coordinator: Yarmarkovich, Mark
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.